Showing 719 results
-
Media Release /Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T…
-
Media Release /
-
Media Release /
-
Media Release /- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
-
Media Release /
-
Media Release /- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible- Using patients' self-recorded measurements, FocalView aims to enable…
-
Media Release /
-
Media Release /-- EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial that meaningfully delayed disability progression in typical secondary progressive MS (…
-
Media Release /
-
Media Release /- Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows(1)- Study findings show absolute PASI ≤1/≤2/≤3…
